Fintel reports that on November 11, 2025, Jones Trading downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Buy to Hold. Analyst Price Forecast Suggests 232.11% Upside As of …
Jones Trading Downgrades Intellia Therapeutics (NTLA)
view original post